EX-99.1 2 abt-2026q2xexhibitx991.htm EX-99.1 Document  Exhibit 99.1    News Release Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance – Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent – Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31 – Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5% 1 – Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58 – Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases ABBOTT PARK, Ill., July 16, 2026 — Abbott today announced financial results for the second quarter ended June 30, 2026. • Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis. • Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items. • Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5% 1 . • Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58. • In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial. This trial is designed to evaluate Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation. • In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company's pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios. • In May, Abbott announced it secured CE Mark for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes. • In May, Abbott completed its submission to the U.S. Food and Drug Administration (FDA) seeking approval for the company's Amulet™ 360 left atrial appendage (LAA) device. • In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options for adults age 45 and older who are at average risk for CRC. "Our second-quarter results reflect the momentum we are building," said Robert B. Ford, chairman and chief executive officer, Abbott. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."   Page 1 of 21 SECOND-QUARTER BUSINESS OVERVIEW Comparable sales growth: Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026. Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. Second Quarter 2026 Results (2Q26) Sales 2Q26 ($ in millions) Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices U.S. 5,216  871  1,660  —  2,680  International 7,377  1,273  1,432  1,499  3,173  Total reported 12,593  2,144  3,092  1,499  5,853  % Change vs. 2Q25 U.S. 22.0  (9.0) 104.8  n/a 7.0  International 7.5  1.4  5.1  8.4  10.7  Total reported 13.0  (3.1) 42.3  8.4  9.0  Total reported excl. foreign exchange impact 12.2  (3.6) 41.3  8.7  7.9  Comparable sales growth 4.8  (3.6) 2.9  8.7  8.4      U.S. 3.5  (9.0) 4.0  n/a 8.0      International 5.8  0.6  1.6  8.7  8.7  First Half 2026 Results (1H26) Sales 1H26 ($ in millions) Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices U.S. 9,490  1,715  2,565  —  5,203  International 14,267  2,446  2,707  2,925  6,189  Total reported 23,757  4,161  5,272  2,925  11,392  % Change vs. 1H25 U.S. 12.4  (10.3) 52.5  n/a 7.4  International 9.3  —  6.4  10.7  14.2  Total reported 10.5  (4.5) 24.7  10.7  11.0  Total reported excl. foreign exchange impact 8.2  (5.6) 22.4  8.9  8.0  Comparable sales growth 4.3  (5.6) 2.4  8.9  8.4      U.S. 3.0  (10.3) 3.0  n/a 8.3      International 5.3  (1.9) 1.6  8.9  8.5  Refer to pages 16 and 17 for a reconciliation of comparable sales growth. Page 2 of 21 Nutrition Second Quarter 2026 Results (2Q26) Sales 2Q26 ($ in millions) Total Pediatric Adult U.S. 871  525  346  International 1,273  500  773  Total reported 2,144  1,025  1,119  % Change vs. 2Q25 U.S. (9.0) (10.7) (6.4) International 1.4  7.3  (2.0) Total reported (3.1) (2.7) (3.4) Total reported excl. foreign exchange impact (3.6) (3.1) (4.0) Comparable sales growth (3.6) (3.1) (4.0)     U.S. (9.0) (10.7) (6.4)     International 0.6  6.4  (2.8) Worldwide Nutrition sales decreased 3.1 percent on a reported basis and 3.6 percent on a comparable basis in the second quarter. Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of new products, are contributing to improving performance. Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026. First Half 2026 Results (1H26) Sales 1H26 ($ in millions) Total Pediatric Adult U.S. 1,715  1,036  679  International 2,446  942  1,504  Total reported 4,161  1,978  2,183  % Change vs. 1H25 U.S. (10.3) (11.9) (7.8) International —  2.4  (1.5) Total reported (4.5) (5.6) (3.5) Total reported excl. foreign exchange impact (5.6) (6.4) (4.9) Comparable sales growth (5.6) (6.4) (4.9)     U.S. (10.3) (11.9) (7.8)     International (1.9) 0.7  (3.5) Page 3 of 21 Diagnostics* Second Quarter 2026 Results (2Q26) Sales 2Q26 ($ in millions) Total Core Laboratory Cancer Diagnostics Rapid/Molecular Diagnostics U.S. 1,660  377  890  393  International 1,432  1,041  29  362  Total reported 3,092  1,418  919  755  % Change vs. 2Q25 U.S. 104.8  7.5  n/a (14.5) International 5.1  3.4  n/a 2.0  Total reported 42.3  4.4  n/a (7.3) Total reported excl. foreign exchange impact 41.3  3.2  n/a (8.0) Comparable sales growth 2.9  3.2  13.3  (8.0)     U.S. 4.0  7.5  13.3  (14.5)     International 1.6  1.7  13.8  0.5  Worldwide Diagnostics sales increased 42.3 percent on a reported basis and 2.9 percent on a comparable basis in the second quarter. Worldwide Core Laboratory Diagnostics results were driven by strong growth in the U.S. and Latin America. Rapid and Molecular Diagnostics results reflect lower sales of respiratory virus tests compared to the prior year. Cancer Diagnostics results were driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat users. Results in the quarter also reflect contributions to growth from the precision oncology and international businesses. First Half 2026 Results (1H26) Sales 1H26 ($ in millions) Total Core Laboratory Cancer Diagnostics Rapid/Molecular Diagnostics U.S. 2,565  724  983  858  International 2,707  1,966  32  709  Total reported 5,272  2,690  1,015  1,567  % Change vs. 1H25 U.S. 52.5  6.0  n/a (14.1) International 6.4  6.1  n/a 2.4  Total reported 24.7  6.1  n/a (7.4) Total reported excl. foreign exchange impact 22.4  3.2  n/a (8.8) Comparable sales growth 2.4  3.2  13.3  (8.8)     U.S. 3.0  6.0  13.2  (14.1)     International 1.6  2.2  16.5  (1.1) *Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business. Refer to pages 16 and 17 for a reconciliation of comparable sales growth. Page 4 of 21 Established Pharmaceuticals Second Quarter 2026 Results (2Q26) Sales 2Q26 ($ in millions) Total Key Emerging Markets Other U.S. —  —  —  International 1,499  1,164  335  Total reported 1,499  1,164  335  % Change vs. 2Q25 U.S. n/a n/a n/a International 8.4  9.8  3.7  Total reported 8.4  9.8  3.7  Total reported excl. foreign exchange impact 8.7  10.7  2.1  Comparable sales growth 8.7  10.7  2.1      U.S. n/a n/a n/a     International 8.7  10.7  2.1  Established Pharmaceuticals sales increased 8.4 percent on a reported basis and 8.7 percent on a comparable basis in the second quarter. Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.8 percent on a reported basis and 10.7 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions. First Half 2026 Results (1H26) Sales 1H26 ($ in millions) Total Key Emerging Markets Other U.S. —  —  —  International 2,925  2,253  672  Total reported 2,925  2,253  672  % Change vs. 1H25 U.S. n/a n/a n/a International 10.7  11.3  8.6  Total reported 10.7  11.3  8.6  Total reported excl. foreign exchange impact 8.9  10.1  4.9  Comparable sales growth 8.9  10.1  4.9      U.S. n/a n/a n/a     International 8.9  10.1  4.9  Page 5 of 21 Medical Devices Second Quarter 2026 Results (2Q26) Sales 2Q26 ($ in millions) Total Rhythm Management Electro-physiology* Heart Failure Vascular Structural Heart* Neuro-modulation Diabetes Care U.S. 2,680  377  420  313  294  225  189  862  International 3,173  366  441  88  509  372  71  1,326  Total reported 5,853  743  861  401  803  597  260  2,188  % Change vs. 2Q25 U.S. 7.0  10.7  15.9  10.9  3.9  (9.8) (2.1) 8.6  International 10.7  10.0  12.3  3.0  7.5  12.1  14.7  11.7  Total reported 9.0  10.4  14.0  9.0  6.1  2.7  2.0  10.5  Total reported excl. foreign exchange impact 7.9  9.5  13.4  8.7  5.1  1.7  1.2  9.0  Comparable sales growth 8.4  9.5  13.4  8.7  5.1  5.7  1.2  9.0      U.S. 8.0  10.7  15.9  10.9  3.9  (0.9) (2.1) 8.6      International 8.7  8.3  11.1  1.3  5.8  10.2  11.3  9.2  Worldwide Medical Devices sales increased 9.0 percent on a reported basis and 8.4 percent on a comparable basis in the second quarter. Sales growth in the quarter was led by low-teens growth in Electrophysiology and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure. In Diabetes Care, sales of continuous glucose monitors grew 11.0 percent on a reported basis and 9.5 percent on a comparable basis. First Half 2026 Results (1H26) Sales 1H26 ($ in millions) Total Rhythm Management Electro-physiology* Heart Failure Vascular Structural Heart* Neuro-modulation Diabetes Care U.S. 5,203  716  798  605  585  449  366  1,684  International 6,189  711  851  185  995  726  137  2,584  Total reported 11,392  1,427  1,649  790  1,580  1,175  503  4,268  % Change vs. 1H25 U.S. 7.4  11.1  14.8  11.1  6.2  (9.6) (0.7) 9.2  International 14.2  15.9  15.7  13.5  8.7  18.1  20.4  14.0  Total reported 11.0  13.4  15.3  11.7  7.7  5.7  4.3  12.1  Total reported excl. foreign exchange impact 8.0  10.9  13.0  10.4  5.0  2.6  2.6  8.2  Comparable sales growth 8.4  10.9  13.0  10.4  5.0  6.2  2.6  8.2      U.S. 8.3  11.1  14.8  11.1  6.2  (2.2) (0.7) 9.2      International 8.5  10.7  11.2  7.8  4.3  12.4  13.2  7.5  *Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology. Refer to pages 16 and 17 for a reconciliation of comparable sales growth. Page 6 of 21 Abbott's Financial Guidance Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% 1 . Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60. Abbott projects third-quarter 2026 adjusted diluted earnings per share of $1.38 to $1.46 . Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP. Abbott Declares 410 th Consecutive Quarterly Dividend On June 12, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026. Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn , Facebook , Instagram , X and YouTube . Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day. Page 7 of 21 — Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Abbott Financial: Michael Comilla, 224-668-1872 Tamika McLoughlin, 224-399-5082 Randy Blakley, 224-668-0036 Abbott Media: Karen Twigg May, 224-668-2681 Kate Dyer, 224-668-9965 1. In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott’s Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million. Page 8 of 21 Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Second Quarter Ended June 30, 2026 and 2025 (in millions, except per share data) (unaudited) 2Q26 2Q25 % Change Net Sales $12,593 $11,142 13.0  Cost of products sold, excluding amortization expense 5,325  4,854  9.7  Amortization of intangible assets 658  420  56.8  Research and development 892  725  22.9  Selling, general, and administrative 4,025  3,091  30.3  Total Operating Cost and Expenses 10,900  9,090  19.9  Operating Earnings 1,693  2,052  (17.5) Interest expense, net 299  50  n/m Net foreign exchange (gain) loss 4  (11) n/m Other (income) expense, net (134) (137) (2.5) Earnings before taxes 1,524  2,150  (29.1) Taxes on Earnings 596  371  60.8  1) Net Earnings $928 $1,779 (47.8) Net Earnings excluding Specified Items, as described below $2,290 $2,213 3.5  2) Diluted Earnings per Common Share $0.53 $1.01 n/m Diluted Earnings per Common Share, excluding Specified Items, as described below $1.31 $1.26 4.0  2) Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,743  1,751  NOTES: See tables on page 13 for an explanation of certain non-GAAP financial information. n/m = Percent change is not meaningful. See footnotes on the following page. Page 9 of 21 1) 2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 2) 2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.362 billion, or $0.78 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, and other net expenses. 2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses. Page 10 of 21 Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings First Half Ended June 30, 2026 and 2025 (in millions, except per share data) (unaudited) 1H26 1H25 % Change Net Sales $23,757 $21,500 10.5  Cost of products sold, excluding amortization expense 10,215  9,322  9.6  Amortization of intangible assets 1,080  840  28.5  Research and development 1,659  1,441  15.1  Selling, general, and administrative 7,765  6,152  26.2  Total Operating Cost and Expenses 20,719  17,755  16.7  Operating Earnings 3,038  3,745  (18.9) Interest expense, net 367  99  n/m Net foreign exchange (gain) loss (9) (18) n/m Other (income) expense, net (293) (264) 10.6  Earnings before taxes 2,973  3,928  (24.3) Taxes on earnings 968  824  17.5  1) Net Earnings $2,005 $3,104 n/m Net Earnings excluding Specified Items, as described below $4,312 $4,132 4.4  2) Diluted Earnings per Common Share $1.14 $1.77 n/m Diluted Earnings per Common Share, excluding Specified Items, as described below $2.46 $2.35 4.7  2) Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options 1,745  1,749  NOTES: See tables on page 14 for an explanation of certain non-GAAP financial information. n/m = Percent change is not meaningful. See footnotes on the following page. Page 11 of 21 1) 2026 Taxes on Earnings includes the recognition of approximately $60 million of